{
    "clinical_study": {
        "@rank": "156397", 
        "arm_group": [
            {
                "arm_group_label": "NaBen\u00ae (Sodium Benzoate)", 
                "arm_group_type": "Experimental", 
                "description": "NaBen\u00ae (Sodium Benzoate) is a white oral tablet (sodium benzoate, 500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The control treatment is placebo, which will look, and will be packaged and maintained exactly the same way as the test treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if NaBen\u00ae (sodium benzoate) is a safe and\n      effective add-on treatment for schizophrenia in adolescents."
        }, 
        "brief_title": "Adaptive Phase II Study to Evaluate the Safety & Efficacy of Sodium Benzoate as an Add-on Treatment for Schizophrenia in Adolescents", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "This is a two-part, multi-center, prospective, randomized, placebo-controlled,\n      parallel-group study, in which adolescent subjects with schizophrenia will be enrolled.\n      Overall, eligible subjects will be randomized in a pre-defined 1:1 ratio to NaBen\u00ae or\n      placebo.\n\n      This study will be conducted in two parts:\n\n      In Part 1 (Phase IIb) of the study, 76 subjects (~ 60% of the total planned subjects) will\n      be randomized in a 1:1 ratio (NaBen\u00ae or placebo), of which 38 subjects will be randomized to\n      the NaBen\u00ae group and 38 subjects to the placebo group.  An interim analysis (IA) will be\n      conducted after the randomization of the 76th subject in Part 1 of the study. The data will\n      be analyzed after all enrolled subjects in Part 1 of the study complete Visit 5 (week 6) or\n      are withdrawn from the study, whichever occurs first. The data from IA will be reviewed by\n      an independent Data Safety and Monitoring Committee (DSMC) that will be responsible for the\n      review of the data from the Part 1 (Phase IIb) of the study for both safety and the\n      effectiveness.\n\n      In Part 2 (Phase III) of the study, a total of 50 subjects will be randomized, of which 25\n      subjects will be randomized to the NaBen\u00ae group and 25 subjects to the placebo group. The\n      final subject numbers in the study will depend on the sample size re-estimation after Part 1\n      of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects who are between 12 and 16 years of age inclusive, who do not\n             have their 17th birthday before the study completion\n\n          -  Physician confirmed DSM-IV or -V diagnosis of schizophrenia based on MINI\n             International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorders\n             Studies for Children and Adolescents, version 6.0 (MINI-KID, Version 6.0)\n\n          -  Are clinically stable with residual symptoms, defined as a total score of \u2265 60 of\n             PANSS and a score of \u2265 40 for SANS\n\n          -  An unchanged anti-psychotic medication regimen for at least eight (8) weeks prior to\n             randomization into the study and expected to remain unchanged during the study\n\n          -  In good general physical health and all physical exam, neurological exam and\n             laboratory assessments (urine/blood routine, biochemical tests and ECG) are\n             clinically unremarkable per the investigator\n\n          -  Subject has a negative urine illicit drug screening test\n\n          -  Subject understands and is willing to sign the Informed Assent Form (IAF) prior to\n             study entry and agrees to be available for all the study visits\n\n          -  The subject's guardian understands and is willing to sign the Informed Consent Form\n             (ICF) prior to study entry and agrees to be available for all the study visits\n\n          -  Must not be a danger to self or others and must have family support available to be\n             maintained as outpatients\n\n        Exclusion Criteria:\n\n          -  Meets the DSM-IV or -V criteria at screening for mental retardation, dissociative\n             disorder, bipolar disorder, major depressive disorder, schizoaffective disorder,\n             schizophreniform disorder, autistic disorder, or primary substance induced psychotic\n             disorder. Other comorbid disorders; e.g., attention-deficit hyperactivity disorder\n             (ADHD), are allowed as long as schizophrenia is the primary diagnosis and the\n             comorbid disorder(s) do not require medication.\n\n          -  Subjects whose illness was resistant to antipsychotics according to prior trials of\n             two different antipsychotics of adequate dose\n\n          -  History of epilepsy, head trauma, or neurological illness other than Tourette's\n             syndrome\n\n          -  History of allergic reaction to sodium benzoate\n\n          -  Serious medical illnesses such as acute or chronic renal disease, liver failure or\n             heart disease that, in the opinion of the investigator, may interfere with the\n             conduct of the study.\n\n          -  Current substance abuse or positive urine illicit drug screening or history of\n             substance dependence (including alcohol, but excluding nicotine and caffeine) in the\n             past three (3) months.\n\n          -  Use of depot antipsychotics in the past six (6) months\n\n          -  Inability to follow protocol\n\n          -  Body Mass Index (BMI) > 35\n\n          -  Female subjects who are pregnant (as confirmed by urine pregnancy test performed at\n             screening Visit) or are nursing, or who do not agree to abstinence or birth control\n             during the study\n\n          -  Cancer within the last three (3) years except for basal cell carcinoma and squamous\n             cell carcinoma\n\n          -  Previous participation in an intervention trial within 30 days of randomization\n\n          -  Subjects whose PANSS score has decreased more than 10 percent during the Screening\n             Phase"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908192", 
            "org_study_id": "SNR-01-NaBen"
        }, 
        "intervention": [
            {
                "arm_group_label": "NaBen\u00ae (Sodium Benzoate)", 
                "description": "The Study Treatment is NaBen\u00ae, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo). The Study Treatment will also include Sodium Benzoate alongside the other ingredients in the Control Treatment (Placebo).", 
                "intervention_name": "NaBen\u00ae (Sodium Benzoate)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient, Sodium Benzoate.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Benzoates", 
                "Sodium Benzoate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Sodium Benzoate", 
            "Schizophrenia", 
            "Adolescent", 
            "Antipsychotic", 
            "Anti-psychotic", 
            "NMDA", 
            "NaBen", 
            "pediatric"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": {
            "description": "The clinical trial management organization", 
            "url": "http://www.amarexcro.com"
        }, 
        "location": {
            "contact": {
                "last_name": "Adelaide S. Robb, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Washington, D.C", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20010"
                }, 
                "name": "Children's National Health System"
            }, 
            "investigator": {
                "last_name": "Adelaide S Robb, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen\u00ae (Sodium Benzoate), A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents", 
        "other_outcome": [
            {
                "measure": "Percent change in Children's Global Assessment Scale (CGAS)", 
                "safety_issue": "No", 
                "time_frame": "Children's Global Assessment Scale will be assessed at Visit 1(Screening), Visit 3, 4, 5, and 6"
            }, 
            {
                "measure": "Percent change in Clinical Global Impression-Severity (CGI-S)", 
                "safety_issue": "No", 
                "time_frame": "Clinical Global Impression will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6"
            }, 
            {
                "measure": "Percent change in Children's Depression Rating Scale-Revised (CDRS-R)", 
                "safety_issue": "No", 
                "time_frame": "Children's Depression Rating Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6"
            }
        ], 
        "overall_contact": {
            "email": "yashars@amarexcro.com", 
            "last_name": "Yashar Salek, MD", 
            "phone": "1-301-956-2527"
        }, 
        "overall_contact_backup": {
            "email": "anandb@amarexcro.com", 
            "last_name": "Anand Balasubramanian, B Pharm.", 
            "phone": "1-301-956-2531"
        }, 
        "overall_official": {
            "affiliation": "Children's National Health System", 
            "last_name": "Adelaide S. Robb, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score after 6 weeks of treatment", 
            "safety_issue": "No", 
            "time_frame": "Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908192"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent change from baseline in Positive and Negative Syndrome Scale (PANSS) total score from baseline after 6 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6."
            }, 
            {
                "measure": "Percentage of subjects with 20% or more reduction in Positive and Negative Syndrome Scale (PANSS) total score from baseline after six (6) weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6"
            }, 
            {
                "measure": "Percent change in Positive and Negative Syndrome Scale (PANSS) sub-scales", 
                "safety_issue": "No", 
                "time_frame": "Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6."
            }, 
            {
                "measure": "Percent change in Scale for Assessment of Negative Symptoms (SANS) total scores", 
                "safety_issue": "No", 
                "time_frame": "Scale for Assessment of Negative Symptoms will be assessed at Visit 1 (Screening), Visit 3,4,5, and 6"
            }, 
            {
                "measure": "Percent change in Scale for Assessment of Negative Symptoms (SANS) sub-scale scores", 
                "safety_issue": "No", 
                "time_frame": "Scale for Assessment of Negative Symptoms will be assessed at Visit 1 (Screening), Visit 3,4,5, and 6"
            }, 
            {
                "measure": "Percent change from baseline in the PANSS total score after 6 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "Positive and Negative Syndrome Scale will be assessed at Visit 1 (Screening), Visit 3, 4, 5, and 6"
            }
        ], 
        "source": "SyneuRx International (Taiwan) Corp", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SyneuRx International (Taiwan) Corp", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}